Ontario invests $5.5 million in healthtech companies

MISSISSAUGA, Ont. – The Ontario government is investing $5.5 million to help 11 companies in the life sciences sector develop and launch made-in-Ontario healthcare technologies and innovations. “These investments signal our government’s continued commitment to promoting the very best of Ontario’s life sciences sector,” said Vic Fedeli (pictured), minister of Economic Development, Job Creation and Trade.

This investment is part of the province’s $15 million Life Sciences Innovation Fund (LSIF), which was created in 2022 to help entrepreneurs and innovators bring their ideas and prototypes from the lab to the marketplace. The 11 companies listed below will each receive $500,000 to help commercialize their technologies:

• Apiary Therapeutics, located in Toronto, has engineered cells that act as advanced drug delivery vehicles for a patient, offering advantages over traditional methods like repeat injections. Cell-based delivery can be more targeted, cost effective and result in better patient compliance.
• Cohesys Inc., located in Toronto, has created a special adhesive bone tape used by orthopedic surgeons in place of plates and screws for non-loadbearing bone fracture repairs. The technology aims to reduce surgery times with better patient outcomes. * Gold Sentintel Inc., located in Waterloo, has advanced AI-powered technology that improves quality of life for seniors living in care by identifying early signs of illness and detecting and preventing falls.
• HDAX Therapeutics, located in Mississauga, is pioneering next-generation therapeutics solutions for diseases driven by microtubule dysfunction to achieve better patient outcomes.
• KVR Pharmaceuticals Inc., located in Toronto, has developed products to treat patients with bleeding disorders and related diseases. The company is also exploring how coagulation medicines could be used in the treatment of cancer.
• Noa Therapeutics Inc., located in Toronto, is developing non-steroidal therapies to transform the treatment of immune diseases.
• Novel Biotechnology Inc., located in Vaughan, has created technology that enhances the manufacture of plasmid DNA, which is used to make vaccines and gene therapies.
• Quthero Canada Ltd., located in Toronto, has leveraged bio-engineering technology that helps skin healing and regeneration for dermatology and plastic surgery patients.
• Radialis Inc., located in Thunder Bay, has developed high-definition positron emission tomography (PET) imagers. The technology creates a very clear image of an area of concern in a patient’s body, which helps the clinical team make the best diagnosis and treatment plan.
• Realize Medical Inc., located in Ottawa, is employing virtual reality technology that uses a patient’s medical images to create 3D models, enabling clinicians working remotely to collaborate and better plan surgeries.
• Tenomix Inc., located in London, is using robotics, ultrasound imaging, AI and machine learning to improve the way cancer tissues are processed in pathology laboratories, leading to better-informed treatment decisions for patients.

“The Life Sciences Innovation Fund demonstrates Ontario’s commitment to advancing the life sciences sector,” said Claudia Krywiak, president and CEO of the Ontario Centre of Innovation. “The achievements to date underscore the importance of strategic investment in fostering innovation, economic growth, and societal impact. OCI remains committed to fostering a vibrant and dynamic ecosystem that supports groundbreaking research, commercialization, and job creation.”

The LSIF is part of the province’s Taking Life Sciences to the Next Level, the government’s life sciences strategy to establish Ontario as a global biomanufacturing and life sciences hub. Ontario has also convened a Life Sciences Council, whose work will help inform the next stages of the life sciences strategy.